Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels

Journal of Urology

Volumn 158, Issue 2, 1997, Pages 319-325

  Vicini, Frank A ^a   Horwitz, Eric M ^a   Gonzalez, Jose ^a   Martinez, Alvaro A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Biochemistry; Prostate specific antigen; Prostatectomy; Prostatic neoplasms; Radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; BEAM THERAPY; CANCER SURVIVAL; DIAGNOSTIC VALUE; HUMAN; INTERSTITIAL RADIATION; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0030793545     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64471-9     Document Type: Review

References (79)

1. Hanks, G. E.: External beam radiation treatment for prostate cancer: still the gold standard. Oncology, 6: 79, 1992.
2. Paulson, D. F.: Randomized series of treatment with surgery versus radiation for prostate adenocarcinoma. Nat. Cancer Inst. Monogr., 7: 127, 1988.
3. Stein, A., deKernion, J. B., Smith, R. B., Dorey, F. and Patel, H.: Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J. Urol., part 2, 147: 942, 1992.
4. Trapasso, J. G., deKernion, J. B., Smith, R. B. and Dorey, F.: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J. Urol., part 2, 152: 1821, 1994.
5. Parker, S. L., Tong, T., Bolden, S. and Wingo, P. A.: Cancer Statistics. CA, 46: 5, 1996.
6. Chavet, B., Felix-Faure, C., Lupsascka, N., Fijuth, J., Brewer, Y., Davin J.-L., Kirscher, S. and Reboul, F.: Prostate specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy. J. Clin. Oncol., 12: 1402, 1994.
7. Fijuth J., Chavet, B., Vincent, P., Felix-Faure, C. and Reboul, F.: Serum prostate-specific antigen in monitoring the response of carcinoma of the prostate to radiation therapy. Radiother. Oncol., 23: 236, 1992.
8. Kavadi, V. S., Zagars, G. K. and Pollack, A.: Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications. Int. J. Rad. Oncol. Biol. Phys., 30: 279, 1994.
9. Kuban D. A., El-Mahdi, A. M. and Schellhammer, P. F.: Prostate specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int. J. Rad. Oncol. Biol. Phys 32: 307, 1995.
10. Lee, W. R., Hanks, G. E., Schultheiss, T. E., Corn, B. W. and Hunt, M. A.: Localized prostate cancer treated by external beam radiotherapy alone: serum PSA driven outcome analysis. J. Clin. Oncol., 13: 464, 1995.
11. Leibel, S. A., Zelefsky, M. J., Kutcher, G. J., Burman, C. M., Kelson, S. and Fuks, Z.: Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: interim report of a phase 1 dose-escalation study. J. Urol., part 2, 152: 1792, 1994.
12. Pisansky, T. M., Cha, S. S., Earle, J. D., Durr, D. E., Kozelsky, T. F., Wieand, H. S. and Oesterling, J. E.: Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J. Clin. Oncol., 11: 2158, 1993.
13. Ritter, M. A., Messing, E. M., Shanahan, T. G., Potts, S., Chappell, R. J. and Kinsella, T. J.: Prostate specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J. Clin. Oncol., 10: 1208, 1992.
14. Russell, K. J., Dunatov, C., Hafermann, M. D., Griffeth, J. T., Polissar, L., Pelton, J., Cole, S. B., Taylor, E. W., Wiens, L. W., Kesh, W. J., Austin-Seymour, M. M., Griffin, B. R., Russell, A. H., Laramore, G. E. and Griffin, T. W.: Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. J. Urol., 146: 1046, 1991.
15. Schellhammer, P. F., El-Mahdi, A. M., Wright, G. L., Kolm, P. and Ragle, R.: Prostate specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of the prostate. Urology, 42: 13, 1993.
16. Zagars, G. K. and von Eschenbach, A. C.: Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy. Cancer, 72: 538, 1993.
17. Zagars, G. K.: Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J. Urol., part 2, 152: 1786, 1994.
18. Zagars, G. K. and Pollack, A.: Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome. Urology, 45: 476, 1995.
19. Zagars, G. K., Pollack, A., Kavadi, V. S. and von Eschenbach, A. C.: Prostate specific antigen and radiation therapy for clinically localized prostate cancer. Int. J. Rad. Oncol. Biol. Phys., 32: 293, 1995.
20. Zeitman, A. L., Coen, J. J., Shipley, W. U., Willett, C. G. and Efrid, J. T.: Radical radiation therapy in the management of prostate adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J. Urol., 151: 640, 1994.
21. Zeitman, A. L., Shipley, W. U. and Coen, J. J.: Radical prostatectomy and radical radiation therapy for clinical stages T1 to T2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen followup. J. Urol., part 2, 152: 1806, 1994.
22. Zeitman, A. L., Coen, J. J., Dallow, K. C. and Shipley, W. U.: The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int. J. Rad. Oncol. Biol. Phys., 32: 287, 1995.
23. Frazier, H. A., Robertson, J. E., Humphrey, P. A. and Paulson, D. F.: Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J. Urol., 149: 516, 1993.
24. Lange, P. H., Ercole, C. J., Lightner, D. J., Fraley, E. E. and Vesella, R.: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J. Urol., 141: 873, 1989.
25. Lerner, S. E., Seay, T. S., Blute, M. L., Bergstralh, E. J., Barrett, D. and Zincke, H.: Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis. J. Urol., 155: 821, 1996.
26. Oesterling, J. E., Chan, D. W., Epstein, J. I., Kimball, A. W., Jr., Bruzek, D. J., Rock, R. C., Brendler, C. B. and Walsh, P. C.: Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J. Urol., 139: 766, 1988.
27. Partin, A. W., Pound, C. R., Clemens, J. Q., Epstein, J. I. and Walsh, P. C.: Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol. Clin. N. Amer., 20: 713, 1993.
28. Zeitman, A. L., Edelstein, R. A., Coen, J. J., Babayan, R. K. and Krane, R. J.: Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology, 43: 828, 1994.
29. Hanks, G. E., D'Amico, A., Epstein, B. E. and Schulteiss, T. E.: Prostatic-specific antigen doubling times in patients with prostate cancer: a potentially useful reflection of tumor doubling time. Int. J. Rad. Oncol. Biol. Phys., 27: 125, 1993.
30. Kaplan, I. D., Cox, R. S. and Bagshaw, M. A.: Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup. J. Urol., 149: 519, 1993.
31. Lightner, D. J., Lange, P. H., Reddy, P. K. and Moore, L.: Prostate specific antigen and local recurrence after radical prostatectomy. J. Urol., 144: 921, 1990.
32. Zagars, G. K.: Serum PSA as a tumor marker for patients undergoing definitive radiation therapy. Urol. Clin. N. Amer., 20: 737, 1993.
33. Morgan, W. R., Bergstralh, E. J. and Zincke, H.: Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology, 41: 113, 1993.
34. 125Iodine implantation for stage T1/T2 prostatic carcinoma. J. Urol., 154: 1096, 1995.
35. Horwitz, E. M., Vicini, F. A., Ziaja, E. L., Gonzalez, J., Dmuchowski, C. F., Stromberg, J. S., Brabbins, D. S., Hollander, J., Chen, P. Y. and Martinez, A. A.: Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Int. J. Rad. Oncol. Biol. Phys., 36: 565, 1996.
36. D'Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Schnall, M., Tomaszewski, J. E. and Wein, A.: A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J. Urol., 154: 131, 1995.
37. Walsh, P. C., Partin, A. W. and Epstein, J. I.: Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J. Urol., part 2, 152: 1831, 1994.
38. Schneider, S. B., Schweitzer, V. G., Parker, R. G. and Bycott, P. W.: The prognostic value of PSA levels in radiation therapy of patients with carcinoma of the prostate: the UCLA experience 1988-1992. Amer. J. Clin. Oncol., 19: 65, 1996.
39. Sandler, H. M., McLaughlin, P. W., Kish, K. E. and Lichter, A. S.: Results of 3D conformal radiotherapy in the treatment of 707 patients with localized prostate cancer. Int. J. Rad. Oncol. Biol. Phys., 32: 141, abstract, 1995.
40. Hanks, G. E., Lee, W. R. and Schultheiss, T.: Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J. Urol., 154: 456, 1995.
41. Corn, B. W., Hanks, G. E., Lee, W. R., Bonin, S. R., Hudes, G. and Schultheiss, T. E.: Prostate specific antigen density is not an independent predictor of response for prostate cancer treated by conformal radiotherapy. J. Urol., 153: 1855, 1995.
42. Stromberg, J., Martinez, A., Gonzalez, J., Edmundson, G., Ohanian, N., Vicini, F., Hollander, J., Gustafson, G., Spencer, W., Yan, D. and Brabbins, D.: Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Int. J. Rad. Oncol. Biol. Phys., 33: 161, 1995.
43. Stock, R. G., Stone, N. N., DeWyngaert, J. K., Lavagnini, P. and Unger, P. D.: Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Cancer, 77: 2386, 1996.
44. 125iodine implantation for localized prostate cancer using percutaneous approach. J. Urol., part 2, 153: 1020, 1995.
45. Goad, J. R., Chang, S. J., Ohori, M. and Scardino, P. T.: PSA after definitive radiotherapy for clinically localized prostate cancer. Urol. Clin. N. Amer., 20: 727, 1993.
46. Cher, M. L., Shinohara, K., Breslin, S., Vapnek, J. and Carroll, P. R.: High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer. Brit. J. Urol., 75: 771, 1995.
47. Gleave, M. E., Goldenberg, S. L., Jones, E. C., Bruchovsky, N. and Sullivan, L. D.: Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J. Urol., 155: 213, 1996.
48. Laramore, G. E., Krall, J. M., Thomas, F. J., Russell, K. J., Maor, M. H., Hendrickson, F. R., Martz, K. L., Griffin, T. W. and Davis, L. W.: Fast neutron radiotherapy for locally advanced prostate cancer. Final report of a Radiation Therapy Oncology Group randomized clinical trial. Amer. J. Clin. Oncol., 16: 164, 1993.
49. Pilepich, M. V., Krall, J., Al-Sarraf, M., Roach, M., Doggett, R. L., Sause, W. T., Lawton, C. A., Abrams, R. A., Rotman, M., Rubin, P. and Shipley, W. U.: A phase III trial of androgen suppression before and during radiation therapy for locally advanced prostatic carcinoma: an interim report. Proc. Amer. Soc. Clin. Oncol., 12: 229, 1993.
50. Pilepich, M. V., Caplan, R., Byhardt, R. W., Lawton, C. A., Gallagher, M. J., Mesic, J. B., Hanks, G. E., Coughlin, C. T. and Porter, A.: Phase III trial of adjuvant androgen suppression using goserelin in patients with carcinoma of the prostate treated with definitive radiotherapy (results of RTOG 85-31). Int. J. Rad. Oncol. Biol. Phys., suppl., 32: 188, abstract 95, 1995.
51. Russell, K. J., Caplan, R. J., Laramore, G. E., Burnison, C. M., Maor, M. H., Taylor, M. E., Zink, S., Davis, L. W. and Griffin, T. W.: Photon versus fast neutron external beam radiotherapy in the treatment of locally advanced prostate cancer: results of a randomized prospective trial. Int. J. Rad. Oncol. Biol. Phys., 28: 47, 1993.
52. Soloway, M. S., Sharifi, R., Wajsman, Z., McLeod, D., Wood, D. P., Jr. and Puras-Baez, A. for the Lupron Depot Neoadjuvant Prostate Cancer Study Group: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J. Urol., 154: 424, 1995.
53. Van Poppel, H., De Ridder, D., Elgamal, A. A., Van de Voorde, W., Werbrouck, P., Ackaert, K., Oyen, R., Pittomvils, G., Baert, L. and Members of the Belgian Uro-Oncological Study Group: Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. J. Urol., 154: 429, 1995.
54. Middleton, R. G., Thompson, I. M., Austenfeld, M. S., Cooner, W. H., Correa, R. J., Gibbons, R. P., Miller, H. C., Oesterling, J. E., Resnick, M. I., Smalley, S. R. and Wasson, J. H.: Prostate Cancer Clinical Guidelines Panel summary report on the management of clinically localized prostate cancer. J. Urol., 154: 2144, 1995.
55. Brawer, M. K. and Lange, P. H.: Prostate specific antigen: its role in early detection, staging, and monitoring of prostatic carcinoma. J. Endourol., 3: 227, 1989.
56. Catalona, W. J., Smith, D. S., Ratcliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J. J., Petros, J. A. and Andriole, G. L.: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New Engl. J. Med., 324: 1156, 1991.
57. Labrie, F., Dupont, A., Suburu, R., Cusan, L., Tremblay, M., Gomez, J.-L. and Emond, J.: Serum prostate specific antigen as a pre-screening test for prostate cancer. J. Urol., 147: 846, 1992.
58. Benson, M. C. and Olsson, C. A.: Prostate specific antigen and prostate specific antigen density. Roles in patient evaluation and management. Cancer, 74: 1667, 1994.
59. Blackwell, K. L., Bostwick, D. G., Myers, R. P., Zincke, H. and Oesterling, J. E.: Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. J. Urol., 151: 1565, 1994.
60. D'Amico, A. V. and Propert, K. J.: Prostate cancer volume adds significantly to prostate-specific antigen in the prediction of early biochemical failure after external beam radiation therapy. Int. J. Rad. Oncol. Biol. Phys., 35: 273, 1996.
61. Nishiya, M., Miller, G. J., Lookner, D. H. and Crawford, E. D.: Prostate specific antigen density in patients with histologically proven prostate carcinoma. Cancer, 74: 3002, 1994.
62. Pollack, A., Lankford, S., Zagars, G. K. and Babaian, R. J.: Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy. Cancer, 77: 1515, 1996.
63. Lerner, S. E., Blute, M. L., Bergstralh, E. J., Bostwick, D. G., Eickholt, J. T. and Zincke, H.: Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical prostatectomy. J. Urol., 156: 137, 1996.
64. Ohori, M., Wheeler, T. M., Kattan, M. W., Goto, Y. and Scardino, P. T.: Prognostic significance of positive surgical margins in radical prostatectomy specimens. J. Urol., 154: 1818, 1995.
65. Hanks, G. E., Perez, C. A., Kozar, M., Asbell, S. O., Pilepich, M. V. and Pajak, T. F.: PSA confirmation of cure at 10 years of T1b, T2, N0, M0 prostate cancer patients treated in RTOG protocol 77-06 with external beam irradiation. Int. J. Rad. Oncol. Biol. Phys., 30: 289, 1994.
66. Cooper, H. M. and Hedges, L. V.: Handbook of Research Synthesis. New York: Russell Sage Foundation, 1993.
67. Kleinbaum, D. G., Kupper, L. L. and Morgenstern, H.: Epidemiologic Research: Principles and Quantitative Methods. New York: Van Nostrand Reinhold, 1982.
68. Wilt, T. J. and Brawer, M. K.: The Prostate Cancer Intervention Versus Observation Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J. Urol., part 2, 152: 1910, 1994.
69. Catalona, W. J., Smith, D. S., Wolfert, R. L., Wang, T. J., Rittenhouse, H. G., Ratliff, T. L. and Nadler, R. B.: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. J.A.M.A., 274: 1214, 1995.
70. Ennis, R., Katz, A., deVries, G., Hsu, I., Buttyan, R., Benson, M., Schiff, P. and Olsson, C.: Detection of circulating prostate cancer cells via reverse transcriptase-polymerase chain reaction (RT-PCR) in patients with clinically localized prostate cancer: independence from other pretreatment characteristics. Proc. Amer. Soc. Clin. Oncol., 14: A643, 1995.
71. Ghossein, R. A., Scher, H. I., Gerald, W. L., Kelly, W. K., Curley, T., Amsterdam, A., Zhang, Z. F. and Rosai, J.: Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J. Clin. Oncol., 13: 1195, 1995.
72. Katz, A. E., Olsson, C. A., Raffo, A. J., Cama, C., Perlman, H., Seaman, E., O'Toole, K. M., McMahon, D., Benson, M. C. and Buttyan, R.: Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology, 43: 765, 1994.
73. Lerner, S. E., Blute, M. L. and Zincke, H.: Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Sem. Urol. Oncol., suppl. 2, 14: 12, 1996.
74. Pollack, A., Zagars, G. K., el-Naggar, A. K. and Terry, N. H.: Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer. Urology, 44: 711, 1994.
75. Partin, A. W., Yee, J., Carter, H. B., Pearson, J. D., Chan, D. W., Epstein, J. I. and Walsh, P. C.: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol., 150: 110, 1993.
76. Potosky, A. L., Miller, B. A., Albertsen, P. C. and Kramer, B. S.: The role of increasing detection in the rising incidence of prostate cancer. J.A.M.A., 273: 548, 1995.
77. Woolf, S. H.: Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. New Engl. J. Med., 333: 1401, 1995.
78. Crook, J., Robertson, S., Collin, G., Zaleski, V. and Esche, B.: Clinical relevance of trans-rectal ultrasound, biopsy, and serum prostate specific antigen following external beam radiotherapy for carcinoma of the prostate. Int. J. Rad. Oncol. Biol. Phys., 27: 31, 1993.
79. Dugan, T. C., Shipley, W. U., Young, R. H., Verhey, L. J., Althausen, A. F., Heney, N. M., McManus, P. L. and Abraham, E. H.: Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: correlation with original histological grade and current prostate specific antigen levels. J. Urol., 146: 1313, 1991.